Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from FranceAdèle de Masson, Sabrina Fourcade-Roch, Marie-Pierre Labarthe et al.|Journal of the American Academy of Dermatology|2020Cited by 189
Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanomaMarius Ilié, Paul Hofman, Élodie Long-Mira et al.|Journal of the American Academy of Dermatology|2015Cited by 38
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Michal Kiciński et al.|The Lancet Oncology|2025Cited by 10
BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez‐Rodas, Stéphane Dalle, Caroline Dutriaux et al.|Journal of Clinical Oncology|2025Cited by 7
Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatmentS. Tzoumpa, E. Maubec, B. Villette et al.|Immunotherapy|2024Cited by 2